In a drug screen to find novel SASP regulators, rapamycin, a selective inhibitor of the mTOR complex 1 (mTORC1), abrogated the induction of a number of SASP components through a mechanism dependent on downregulation of mitogen-activated protein kinase-activated protein kinase 2 (MAP-KAPK2 or MK2), a downstream effector of p38, thereby reducing breast tumor growth in mice [190]. The gene discussed is MAPKAPK2; the disease is breast neoplasm.